Potential microRNA targets for cancer chemotherapy

Current Medicinal Chemistry

Volumn 20, Issue 29, 2013, Pages 3574-3581

  Tan, Subee ^a   Wu, Yihan ^a   Zhang, Chen Yu ^a   Li, Jinbo ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Cancer chemotherapy.; Down regulation; MicroRNA; Oncogenic; Tumor suppressive; Tumorigenesis; Up regulation

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ANTINEOPLASTIC AGENT; BETA CATENIN; BIM PROTEIN; CADHERIN; CADHERIN 1; FAS ANTIGEN; MICRORNA; MICRORNA 143; MICRORNA 145; MICRORNA 155; MICRORNA 15A; MICRORNA 16; MICRORNA 192; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 9; MICRORNA 92A; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P130; SMALL UNTRANSLATED RNA; SOMATOMEDIN; TRANSCRIPTION FACTOR CDX2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT3A PROTEIN;

APOPTOSIS; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PATIENT; CARCINOGENESIS; CELL ADHESION; CELL PROLIFERATION; CHEMICAL MODIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; GENE TARGETING; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASM; PLASMA CELL; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; TUMOR SUPPRESSOR GENE;

ANIMALS; DOWN-REGULATION; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84883253282     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320290003     Document Type: Article

References (83)

1. Bartel, D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004, 116, 281-297.
2. He, L.; Hannon, G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet., 2004, 5, 522-531.
3. Winter, J.; Jung, S.; Keller, S.; Gregory, R.I.; Diederichs, S. Many road to maturity: microRNA biogenesis pathways and their regulation. Nat. Cell Biol., 2009, 11, 228-233.
4. Ali, A.S.; Ali, S.; Ahmad, A.; Bao, B.; Philip, P.A.; Sarkar, F.H. Expression of microRNAs: potential molecular link between obesity, diabetes and cancer. Obes. Rev., 2011., 12, 1050-1062.
5. Gupta, A.; Swaminathan, G.; Martin-Garcia, J.; Navas-Martin, S. MicroRNAs, Hepatitis C Virus, and HCV/HIV-1 Co-Infection: New Insights in Pathogenesis and Therapy. Viruses, 2012, 4, 2485-2513.
6. Harraz, M.M.; Dawson, T.M.; Dawson, V.L. MicroRNAs in Parkinson's disease. J. Chem. Neuroanat., 2011, 42, 127-130.
7. Pauley, K.M.; Cha, S.; Chan, E.K. MicroRNA in autoimmunity and autoimmune diseases. J. Autoimmun., 2009, 32, 189-194.
8. Satoh, J. MicroRNAs and their therapeutic potential for human diseases: aberrant microRNA expression in Alzheimer's disease brains. J. Pharmacol. Sci., 2010, 114, 269-275.
9. Small, E.M.; Frost, R.J.A.; Olson, E.N. MicroRNAs Add a New Dimension to Cardiovascular Disease. Circulation, 2010, 121, 1022-1032.
10. Calin, G.A.; Croce, C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer., 2006, 6, 857-866.
11. Cho, W.C.S. MicroRNAs: Potential biomarkers for cancer diagnosis, prognosis and targets f or therapy. Int. J. Biochem. Cell Biol., 2010, 42, 1273-1281.
12. Zen, K.; Zhang, C.-Y. Circulating MicroRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med. Res. Rev., 2012, 32, 326-348.
13. Cheng, C.J.; Slack, F.J. The duality of oncomiR addiction in the maintenance and treatment of cancer. Cancer J., 2012, 18, 232-237.
14. Pan, X.A.; Wang, Z.X.; Wang, R. MicroRNA-21 A novel therapeutic target in human cancer. Cancer Biol. Ther., 2010, 10, 1224-1232.
15. Reis, P.P.; Tomenson, M.; Cervigne, N.K.; Machado, J.; Jurisica, I.; Pintilie, M.; Sukhai, M.A.; Perez-Ordonez, B.; Grénman, R.; Gilbert, R.W.; Gullane, P.J.; Irish, J.C.; Kamel-Reid, S. Programmed cell death 4 loss increases tumor cell invasion and is regulated by miR-21 in oral squamous cell carcinoma. Mol. Cancer., 2010, 9, 238.
16. Chusorn, P.; Namwat, N.; Loilome, W.; Techasen, A.; Pairojkul, C.; Khuntikeo, N.; Dechakhamphu, A.; Talabnin, C.; Chan-On, W.; Ong, C.K.; Teh, B.T.; Yongvanit, P. Overexpression of microRNA-21 regulating PDCD4 during tumorigenesis of liver flukeassociated cholangiocarcinoma contributes to tumor growth and metastasis. Tumour Biol., 2013, 1-10.
17. Medina, P.P.; Nolde, M.; Slack, F.J. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature, 2010, 467, 86-90.
18. Rotkrua, P.; Akiyama, Y.; Hashimoto, Y.; Otsubo, T.; Yuasa, Y. MiR-9 downregulates CDX2 expression in gastric cancer cells. Int. J. Cancer, 2011, 129, 2611-2620.
19. Ma, L.; Young, J.; Prabhala, H.; Pan, E.; Mestdagh, P.; Muth, D.; Teruya-Feldstein, J.; Reinhardt, F.; Onder, T.T.; Valastyan, S.; Westermann, F.; Speleman, F.; Vandesompele, J.; Weinberg, R.A. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol., 2010, 12, 247-56.
20. Poltronieri, P.; D'Urso, P.I.; Mezzolla, V.; D'Urso, O.F. Potential of anti-cancer therapy based on anti-miR-155 oligonucleotides in glioma and brain tumours. Chem. Biol. Drug Des., 2013, 81, 79-84.
21. Jiang, S.A.; Zhang, H.W.; Lu, M.H.; He, X.H.; Li, Y.; Gu, H.; Liu, M.F.; Wang, E.D. MicroRNA-155 Functions as an OncomiR in Breast Cancer by Targeting the Suppressor of Cytokine Signaling 1 Gene. Cancer Res., 2010, 70, 3119-3127.
22. Hummel, R.; Maurer, J.; Haier, J. MicroRNAs in brain tumors : a new diagnostic and therapeutic perspective? Mol. Neurobiol., 2011, 44, 223-234.
23. Garofalo, M.; Quintavalle, C.; Romano, G.; Croce, C.M.; Condorelli, G. miR221/222 in Cancer: Their Role in Tumor Progression and Response to Therapy. Curr. Mol. Med., 2012, 12, 27-33.
24. Concepcion, C.P.; Bonetti, C.; Ventura, A. The microRNA-17-92 family of microRNA clusters in development and disease. Cancer J., 2012, 18, 262-267.
25. Chen, L.; Li, C.; Zhang, R.; Gao, X.; Qu, X.; Zhao, M.; Qiao, C.; Xu, J.; Li, J. miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. Cancer Lett., 2011, 309, 62-70.
26. Hayashita, Y.; Osada, H.; Tatematsu, Y.; Yamada, H.; Yanagisawa, K.; Tomida, S.; Yatabe, Y.; Kawahara, K.; Sekido, Y.; Takahashi, T. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res., 2005, 65, 9628-9632.
27. Diosdado, B.; van de Wiel, M.A.; Terhaar Sive Droste, J.S.; Mongera, S.; Postma, C.; Meijerink, W.J.; Carvalho, B.; Meijer, G.A. MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br. J. Cancer., 2009, 101, 707-714.
28. Xiao, C.; Srinivasan, L.; Calado, D.P.; Patterson, H.C.; Zhang, B.; Wang, J.; Henderson, J.M.; Kutok, J.L.; Rajewsky, K. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat. Immunol., 2008, 9, 405-414.
29. Tsuchida, A.; Ohno, S.; Wu, W.; Borjigin, N.; Fujita, K.; Aoki, T.; Ueda, S.; Takanashi, M.; Kuroda, M. miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer. Cancer Sci., 2011, 102, 2264-2271.
30. Ma, Y.; Zhang, P.; Wang, F.; Zhang, H.; Yang, Y.; Shi, C.; Xia, Y.; Peng, J.; Liu, W.; Yang, Z.; Qin, H. Elevated oncofoetal miR-17-5p expression regulates colorectal cancer progression by repressing its target gene P130. Nat. Commun., 2012, 3, 1291.
31. Olive, V.; Bennett, M.J.; Walker, J.C.; Ma, C.; Jiang, I.; Cordon-Cardo, C.; Li, Q.J.; Lowe, S.W.; Hannon, G.J.; He, L. miR-19 is a key oncogenic component of mir-17-92. Genes Dev., 2009, 23, 2839-2849.
32. Kang, H.W.; Wang, F.; Wei, Q.; Zhao, Y.F.; Liu, M.; Li, X.; Tang, H. miR-20a promotes migration and invasion by regulating TNKS2 in human cervical cancer cells. FEBS Lett., 2012, 586, 897-904.
33. Huang, G.; Nishimoto, K.; Zhou, Z.; Hughes, D.; Kleinerman, E.S. miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res., 2012, 72, 908-916.
34. Takamizawa, J.; Konishi, H.; Yanagisawa, K.; Tomida, S.; Osada, H.; Endoh, H.; Harano, T.; Yatabe, Y.; Nagino, M.; Nimura, Y.; Mitsudomi, T.; Takahashi, T. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res., 2004, 64, 3753-3756.
35. Johnson, S.M.; Grosshans, H.; Shingara, J.; Byrom, M.; Jarvis, R.; Cheng, A.; Labourier, E.; Reinert, K.L.; Brown, D.; Slack, F.J. RAS is regulated by the let-7 MicroRNA family. Cell, 2005, 120, 635-647.
36. He, L.; He, X.; Lim, L.P.; de Stanchina, E.; Xuan, Z.; Liang, Y.; Xue, W.; Zender, L.; Magnus, J.; Ridzon, D.; Jackson, A.L.; Linsley, P.S.; Chen, C.; Lowe, S.W.; Cleary, M.A.; Hannon, G.J. A microRNA component of the p53 tumour suppressor network. Nature, 2007, 447, 1130-1134.
37. Ji, Q.; Hao, X.B.; Zhang, M.; Tang, W.H.; Meng, Y.; Li, L.; Xiang, D.B.; DeSano, J.T.; Bommer, G.T.; Fan, D.M.; Fearon, E.R.; Lawrence, T.S.; Xu, L. MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells. Plos One, 2009, 4, e6816.
38. Liu, C.; Kelnar, K.; Liu, B.; Chen, X.; Calhoun-Davis, T.; Li, H.; Patrawala, L.; Yan, H.; Jeter, C.; Honorio, S.; Wiggins, J.F.; Bader, A.G.; Fagin, R.; Brown, D.; Tang, D.G. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med., 2011, 17, 211-215.
39. Pichiorri, F.; Suh, S.S.; Rocci, A.; De Luca, L.; Taccioli, C.; Santhanam, R.; Zhou, W.; Benson, D.M. Jr.; Hofmainster, C.; Alder, H.; Garofalo, M.; Di Leva, G.; Volinia, S.; Lin, H.J.; Perrotti, D.; Kuehl, M.; Aqeilan, R.I.; Palumbo, A.; Croce, C.M. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell, 2010, 18, 367-381.
40. Aqeilan, R.I.; Calin, G.A.; Croce, C.M. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ., 2009, 17, 215-220.
41. Michael, M.Z.; SM, O.C.; van Holst Pellekaan, N.G.; Young, G.P.; James, R.J. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol. Cancer Res., 2003, 1, 882-891.
42. Phillips, W.A.; Takaoka, Y.; Shimizu, Y.; Hasegawa, H.; Ouchi, Y.; Qiao, S.; Nagahara, M.; Ichihara, M.; Lee, J.-D.; Adachi, K.; Hamaguchi, M.; Iwamoto, T. Forced Expression of miR-143 Represses ERK5/c-Myc and p68/p72 Signaling in Concert with miR-145 in Gut Tumors of ApcMin Mice. Plos One, 2012, 7, e42137.
43. Bader, A.G.; Brown, D.; Winkler, M. The Promise of MicroRNA Replacement Therapy. Cancer Res., 2010, 70, 7027-7030.
44. Henry, J.C.; Azevedo-Pouly, A.C.P.; Schmittgen, T.D. microRNA Replacement Therapy for Cancer. Pharm. Res., 2011, 28, 3030-3042.
45. Ji, Q.; Hao, X.B.; Meng, Y.; Zhang, M.; DeSano, J.; Fan, D.M.; Xu, L. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer, 2008, 8, 266.
46. He, X.X.; Chang, Y.; Meng, F.Y.; Wang, M.Y.; Xie, Q.H.; Tang, F.; Li, P.Y.; Song, Y.H.; Lin, J.S. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene, 2012, 31, 3357-3369.
47. Kitade, Y.; Akao, Y. MicroRNAs and Their Therapeutic Potential for Human Diseases: MicroRNAs, miR-143 and-145, Function as Anti-oncomirs and the Application of Chemically Modified miR-143 as an Anti-cancer Drug. J. Pharmacol. Sci. (Tokyo, Jpn.), 2010, 114, 276-280.
48. Esquela-Kerscher, A.; Trang, P.; Wiggins, J.F.; Patrawala, L.; Cheng, A.G.; Ford, L.; Weidhaas, J.B.; Brown, D.; Bader, A.G.; Slack, F.J. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell cycle (Georgetown, Tex ), 2008, 7, 759-764.
49. Kumar, M.S.; Erkeland, S.J.; Pester, R.E.; Chen, C.Y.; Ebert, M.S.; Sharp, P.A.; Jacks, T. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 3903-3908.
50. Bonci, D.; Coppola, V.; Musumeci, M.; Addario, A.; Giuffrida, R.; Memeo, L.; D'Urso, L.; Pagliuca, A.; Biffoni, M.; Labbaye, C.; Bartucci, M.; Muto, G.; Peschle, C.; De Maria, R. The miR-15amiR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med., 2008, 14, 1271-1277.
51. Kasar, S.; Salerno, E.; Yuan, Y.; Underbayev, C.; Vollenweider, D.; Laurindo, M.F.; Fernandes, H.; Bonci, D.; Addario, A.; Mazzella, F.; Raveche, E. Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia. Genes Immun., 2012, 13, 109-119.
52. Kota, J.; Chivukula, R.R.; O'Donnell, K.A.; Wentzel, E.A.; Montgomery, C.L.; Hwang, H.W.; Chang, T.C.; Vivekanandan, P.; Torbenson, M.; Clark, K.R.; Mendell, J.R.; Mendell, J.T. Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model. Cell, 2009, 137, 1005-1017.
53. Wiggins, J.F.; Ruffino, L.; Kelnar, K.; Omotola, M.; Patrawala, L.; Brown, D.; Bader, A.G. Development of a Lung Cancer Therapeutic Based on the Tumor Suppressor MicroRNA-34. Cancer Res., 2010, 70, 5923-5930.
54. Trang, P.; Wiggins, J.F.; Daige, C.L.; Cho, C.; Omotola, M.; Brown, D.; Weidhaas, J.B.; Bader, A.G.; Slack, F.J. Systemic Delivery of Tumor Suppressor microRNA Mimics Using a Neutral Lipid Emulsion Inhibits Lung Tumors in Mice. Mol. Ther., 2011, 19, 1116-1122.
55. Craig, V.J.; Tzankov, A.; Flori, M.; Schmid, C.A.; Bader, A.G.; Muller, A. Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. Leukemia, 2012, 26, 2421-2424.
56. Pramanik, D.; Campbell, N.R.; Karikari, C.; Chivukula, R.; Kent, O.A.; Mendell, J.T.; Maitra, A. Restitution of Tumor Suppressor MicroRNAs Using a Systemic Nanovector Inhibits Pancreatic Cancer Growth in Mice. Mol. Cancer Ther., 2011, 10, 1470-1480.
57. Ibrahim, A.F.; Weirauch, U.; Thomas, M.; Grunweller, A.; Hartmann, R.K.; Aigner, A. MicroRNA Replacement Therapy for miR-145 and miR-33a Is Efficacious in a Model of Colon Carcinoma. Cancer Res., 2011, 71, 5214-5224.
58. Chiou, G.Y.; Cherng, J.Y.; Hsu, H.S.; Wang, M.L.; Tsai, C.M.; Lu, K.H.; Chien, Y.; Hung, S.C.; Chen, Y.W.; Wong, C.I.; Tseng, L.M.; Huang, P.I.; Yu, C.C.; Hsu, W.H.; Chiou, S.H. Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma. J. Controlled Release, 2012, 159, 240-250.
59. Boutla, A.; Delidakis, C.; Tabler, M. Developmental defects by antisense-mediated inactivation of micro-RNAs 2 and 13 in Drosophila and the identification of putative target genes. Nucleic Acids Res., 2003, 31, 4973-4980.
60. Horwich, M.D.; Zamore, P.D. Design and delivery of antisense oligonucleotides to block microRNA function in cultured Drosophila and human cells. Nat. Protoc., 2008, 3, 1537-1549.
61. Hutvagner, G.; Simard, M.J.; Mello, C.C.; Zamore, P.D. Sequencespecific inhibition of small RNA function. PLoS Biol., 2004, 2, 465-475.
62. Wengel, J.; Koshkin, A.; Singh, S.K.; Nielsen, P.; Meldgaard, M.; Rajwanshi, V.K.; Kumar, R.; Skouv, J.; Nielsen, C.B.; Jacobsen, J.P.; Jacobsen, N.; Olsen, C.E. LNA (Locked Nucleic Acid). Nucleosides Nucleotides, 1999, 18, 1365-1370.
63. Orom, U.A.; Kauppinen, S.; Lund, A.H. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene, 2006, 372, 137-141.
64. Stenvang, J.; Silahtaroglu, A.N.; Lindow, M.; Elmen, J.; Kauppinen, S. The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Semin. Cancer Biol., 2008, 18, 89-102.
65. Elmen, J.; Lindow, M.; Silahtaroglu, A.; Bak, M.; Christensen, M.; Lind-Thomsen, A.; Hedtjarn, M.; Hansen, J.B.; Hansen, H.F.; Straarup, E.M.; McCullagh, K.; Kearney, P.; Kauppinen, S. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res., 2008, 36, 1153-1162.
66. Lanford, R.E.; Hildebrandt-Eriksen, E.S.; Petri, A.; Persson, R.; Lindow, M.; Munk, M.E.; Kauppinen, S.; Orum, H. Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection. Science, 2010, 327, 198-201.
67. Reesink, H.W.; Janssen, H.L.A.; Zeuzem, S.; Lawitz, E.; Rodriguez-Torres, M.; Patel, K.; Chen, A.; Davis, C.; King, B.; Levin, A.; Hodges, M.R. Final Results-Randomized, Double-Blind, Placebo-Controlled Safety, Anti-Viral Proof-of-Concept Study of Miravirsen, an Oligonucleotide Targeting Mir-122, in Treatment-Naive Patients with Genotype 1 Chronic Hcv Infection. J. Hepatol., 2012, 56, S26-S26.
68. Krützfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K.G.; Tuschl, T.; Manoharan, M.; Stoffel, M.Silencing of microRNAs in vivo with 'antagomirs'. Nature, 2005, 438, 685-689.
69. Fontana, L.; Fiori, M.E.; Albini, S.; Cifaldi, L.; Giovinazzi, S.; Forloni, M.; Boldrini, R.; Donfrancesco, A.; Federici, V.; Giacomini, P.; Peschle, C.; Fruci, D. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. Plos One, 2008, 3, e2236.
70. Shu, M.; Zheng, X.; Wu, S.; Lu, H.; Leng, T.; Zhu, W.; Zhou, Y.; Ou, Y.; Lin, X.; Lin, Y.; Xu, D.; Yan, G. Targeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cells. Mol. Cancer, 2011, 10, 59.
71. Reichel, M.; Li, J.Y.; Millar, A.A. Silencing the silencer: strategies to inhibit microRNA activity. Biotechnol. Lett., 2011, 33, 1285-1292.
72. Mighell, A.J.; Smith, N.R.; Robinson, P.A.; Markham, A.F. Vertebrate pseudogenes. FEBS Lett., 2000, 468, 109-114.
73. Poliseno, L.; Salmena, L.; Zhang, J.W.; Carver, B.; Haveman, W.J.; Pandolfi, P.P. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature, 2010, 465, 1033-1038.
74. Wang, Z. The principles of MiRNA-masking antisense oligonucleotides technology. Methods Mol. Biol., 2011, 676, 43-49.
75. Choi, W.Y.; Giraldez, A.J.; Schier, A.F. Target protectors reveal dampening and balancing of nodal agonist and antagonist by miR-430. Science, 2007, 318, 271-274.
76. Liu, X.Q.; Song, W.J.; Sun, T.M.; Zhang, P.Z.; Wang, J. Targeted Delivery of Antisense Inhibitor of miRNA for Antiangiogenesis Therapy Using cRGD-Functionalized Nanoparticles. Mol. Pharm., 2011, 8, 250-259.
77. Chen, Y.C.; Zhu, X.D.; Zhang, X.J.; Liu, B.; Huang, L. Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy. Mol. Ther., 2010, 18, 1650-1656.
78. Chen, X.; Huang, C.; Zhang, W.; Wu, Y.; Zhang, C.Y.; Zhang, Y. A universal activator of microRNAs identified from photoreaction products. Chem. Commun., 2012, 48, 6432-6434.
79. Watashi, K.; Yeung, M.L.; Starost, M.F.; Hosmane, R.S.; Jeang, K.T. Identification of Small Molecules That Suppress MicroRNA Function and Reverse Tumorigenesis. J. Biol. Chem., 2010, 285, 24707-24716.
80. Bose, D.; Jayaraj, G.; Suryawanshi, H.; Agarwala, P.; Pore, S.K.; Banerjee, R.; Maiti, S. The Tuberculosis Drug Streptomycin as a Potential Cancer Therapeutic: Inhibition of miR-21 Function by Directly Targeting Its Precursor. Angew. Chem. Int. Ed., 2012, 51, 1019-1023.
81. Melo, S.; Villanueva, A.; Moutinho, C.; Davalos, V.; Spizzo, R.; Ivan, C.; Rossi, S.; Setien, F.; Casanovas, O.; Simo-Riudalbas, L.; Carmona, J.; Carrere, J.; Vidal, A.; Aytes, A.; Puertas, S.; Ropero, S.; Kalluri, R.; Croce, C.M.; Calin, G.A.; Esteller, M. Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc. Natl. Acad. Sci. U. S. A., 2011, 108, 4394-4399.
82. Li, Y.W.; Kong, D.J.; Wang, Z.W.; Sarkar, F.H. Regulation of microRNAs by Natural Agents:An Emerging Field in Chemoprevention and Chemotherapy Research. Pharm. Res., 2010, 27, 1027-1041.
83. Rushworth, S.A. Targeting the oncogenic role of miRNA in human cancer using naturally occurring compounds. Br. J. Pharmacol., 2011, 162, 346-348.